<div id="readability-page-1"><p>McAdam LLC acquired a new stake in shares of  Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) in the first quarter, according to the company in its most recent filing with the SEC. The firm acquired 2,194 shares of the company's stock, valued at approximately $256,000.</p><ul><li>5 medical stocks growing earnings by triple digits</li></ul><p>Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Caitong International Asset Management Co. Ltd bought a new stake in shares of  Axsome Therapeutics in the 1st quarter valued at about $25,000.  Quantbot Technologies LP bought a new stake in shares of  Axsome Therapeutics in the 1st quarter valued at about $31,000.  NBC Securities Inc. bought a new stake in shares of  Axsome Therapeutics in the 1st quarter valued at about $31,000.  AlphaQuest LLC bought a new stake in shares of  Axsome Therapeutics in the 1st quarter valued at about $38,000.  Finally, Neo Ivy Capital Management bought a new stake in shares of  Axsome Therapeutics in the 1st quarter valued at about $41,000. Institutional investors own  81.49% of the company's stock. </p><div><p><span></span><span>Get <strong>Axsome Therapeutics</strong> alerts:</span></p></div><h2>Wall Street Analyst Weigh In</h2><p>Several equities research analysts have recently commented on the stock. HC Wainwright  restated a &#34;buy&#34; rating and issued a $180.00 price target on shares of Axsome Therapeutics in a report on Tuesday, June 10th. Oppenheimer assumed coverage on shares of Axsome Therapeutics in a report on Tuesday, June 3rd. They issued an &#34;outperform&#34; rating and a $185.00 price target for the company. Royal Bank Of Canada boosted their price target on shares of Axsome Therapeutics from $184.00 to $189.00 and gave the company an &#34;outperform&#34; rating in a report on Tuesday, August 5th. Wells Fargo &amp; Company raised shares of Axsome Therapeutics to a &#34;strong-buy&#34; rating in a research report on Wednesday, September 3rd. Finally, Needham &amp; Company LLC  reaffirmed a &#34;buy&#34; rating and issued a $150.00 price objective on shares of Axsome Therapeutics in a research report on Monday, August 4th. Two investment analysts have rated the stock with a Strong Buy rating and thirteen have issued  a Buy rating to the company's stock. According to MarketBeat.com, the stock  has a consensus rating of &#34;Buy&#34; and an average price target of $177.86.</p><ul><li>Struggling Axsome Stock Could Bounce Back on Drug Trial Success</li></ul><p><b>Read Our Latest Analysis on Axsome Therapeutics</b></p><h2>Insider Activity at Axsome Therapeutics</h2><p>In other Axsome Therapeutics news, General Counsel Hunter R. Murdock sold 6,014 shares of the business's stock in a transaction that occurred on Monday, June 23rd. The shares were sold at an average price of $100.12, for a total transaction of $602,121.68. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Mark Coleman bought 1,575 shares of the company's stock in a transaction on Monday, September 8th. The shares were bought at an average cost of $127.28 per share, for a total transaction of $200,466.00. Following the transaction, the director owned 48,212 shares in the company, valued at $6,136,423.36. The trade was a 3.38% increase in their position. The disclosure for this purchase can be found here. Insiders sold a total of 100,299 shares of company stock worth $11,766,554 in the last quarter. 22.30% of the stock is currently owned by company insiders. </p><h2>Axsome Therapeutics Stock Down 0.9%</h2><ul><li>Why this is an Awesome Time to Buy Axsome Therapeutics</li></ul><p>NASDAQ:AXSM opened at $122.96 on Friday. The company has a market cap of $6.14 billion, a PE ratio of -24.25 and a beta of 0.54. Axsome Therapeutics, Inc. has a twelve month low of $75.56 and a twelve month high of $139.13. The company has a current ratio of 1.57, a quick ratio of 1.51 and a debt-to-equity ratio of 1.66. The company's 50 day moving average is $111.93 and its two-hundred day moving average is $110.87. </p><p>Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last released its earnings results on Monday, August 4th. The company reported ($0.92) earnings per share for the quarter, topping the consensus estimate of ($1.00) by $0.08. The company had revenue of $150.04 million for the quarter, compared to the consensus estimate of $140.02 million. Axsome Therapeutics had a negative net margin of 49.88% and a negative return on equity of 283.22%.  Analysts anticipate that  Axsome Therapeutics, Inc. will post -2.79 EPS for the current year. </p><h2>Axsome Therapeutics Company Profile</h2> (Free Report)<p>Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.</p><h2>Further Reading</h2><ul><li>Five stocks we like better than Axsome Therapeutics</li><li>Want to Profit on the Downtrend? Downtrends, Explained.</li><li>High-Flyers Near Resistance: 3 Stocks to Watch for a Dip</li><li>3 REITs to Buy and Hold for the Long Term</li><li>Seagate Technology Leads S&amp;P 500: What’s Behind Its 120% Gain?</li><li>Utilities Stocks Explained – How and Why to Invest in Utilities</li><li>Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVhTTQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVhTTQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Axsome Therapeutics Right Now?</h2><p>Before you consider Axsome Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Axsome Therapeutics wasn't on the list.</p><p>While Axsome Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

AXSM

<p>McAdam LLC has acquired a new stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM), purchasing 2,194 shares valued at approximately $256,000. Other institutional investors have also increased their stakes. Analysts have given the stock a consensus rating of "Buy" with an average price target of $177.86. Despite a recent stock decline of 0.9%, Axsome reported better-than-expected earnings, with revenue of $150.04 million for the last quarter. The company continues to develop therapies for CNS disorders.</p>

McAdam LLC Acquires New Position in Axsome Therapeutics, Inc. $AXSM